McDonald Criteria for Multiple Sclerosis (2017 Revision)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- MS Not Diagnosed0–0
- MS Diagnosed1–1
- Possible MS2–2
The McDonald Criteria for Multiple Sclerosis (2017 Revision) calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include clinical attacks. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses multiple sclerosis using clinical attacks, lesion characteristics, and MRI findings. The 2017 revision introduces key changes including the use of CSF oligoclonal bands to substitute for dissemination in time, acceptance of symptomatic lesions in brainstem/spinal cord, and inclusion of cortical lesions for dissemination in space criteria.
Clinical Indication
The McDonald Criteria for Multiple Sclerosis (2017 Revision) is indicated for bedside clinical practice to support Diagnoses multiple sclerosis using clinical attacks, lesion characteristics, and MRI findings. The 2017 revision introduces key changes including the use of CSF oligoclonal bands to substitute for dissemination in time, acceptance of symptomatic lesions in brainstem/spinal cord, and inclusion of cortical lesions for dissemination in space criteria.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.
Limitations & Contraindications
Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis. Clinical exclusion: Alternative diagnosis must be adequately excluded to make MS diagnosis.
Clinical Pearls & Action Plan
Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Criteria aim to facilitate earlier diagnosis while preserving specificity.
Diagnosis based on: Clinical attacks (≥1) + Objective clinical evidence + Dissemination in Space (DIS) + Dissemination in Time (DIT or CSF oligoclonal bands) + Exclusion of alternative diagnoses
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| clinical_attacks | string | Yes | Number of clinical attacks. Clinical attack defined as inflammatory demyelinating CNS event lasting ≥24 hours with objective neurological dysfunction |
| objective_clinical_evidence | string | Yes | Number of lesions with objective clinical evidence. Evidence includes abnormality on neurologic exam, imaging, or visual evoked potentials |
| dissemination_in_space | string | Yes | Dissemination in Space (DIS) - Evidence of lesions in multiple CNS locations. Requires ≥1 T2-hyperintense lesions in ≥2 of 4 locations: periventricular, cortical/juxtacortical, infratentorial, spinal cord |
| dissemination_in_time | string | Yes | Dissemination in Time (DIT) - Additional clinical attack, new T2/gadolinium-enhancing lesion on follow-up MRI, or simultaneous gadolinium-enhancing and non-enhancing lesions on single MRI |
| csf_oligoclonal_bands | string | Yes | CSF-specific oligoclonal bands present. In 2017 revision, can substitute for dissemination in time when dissemination in space is demonstrated |
| alternative_diagnosis | string | Yes | Alternative diagnosis that better explains the clinical presentation and findings |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | MS Not Diagnosed | Criteria not met |
| 1–1 | MS Diagnosed | Criteria fulfilled |
| 2–2 | Possible MS | Insufficient criteria |
Evidence-Based References (EBM)
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2.DOI: 10.1016/S1474-4422(17)30470-2
- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.DOI: 10.1002/ana.22366
- McNicholas N, McGuigan C, Kehoe L, Gallagher L, Teeling M, Hamid SH, et al. Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis. J Clin Neurol. 2018 Jul;14(3):387-398. doi: 10.3988/jcn.2018.14.3.387.DOI: 10.3988/jcn.2018.14.3.387
- Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Rio J, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006.DOI: 10.1093/brain/awy006